Top

Published in:

01-11-2004 | Original Article

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

Authors: P. J. Russell, K. T. Ow, P. N. Tam, J. Juarez, E. A. Kingsley, C. F. Qu, Y. Li, P. J. Cozzi, R. Martiniello-Wilks

Published in: Cancer Immunology, Immunotherapy | Issue 11/2004

Abstract

Background: Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies. Methods: BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on patient specimens from normal tissues and cancers was tested by immunohistochemistry using fresh frozen tissues or paraffin-embedded tissues that had undergone antigen retrieval. Results: Cell surface BLCA-38 antigen expression was seen on DU-145, PC-3, PC-3 M and PC-3 M-MM2 prostate cancer lines, but LNCaP, MDA PCa 2a or MDA PCa 2b lines were negative. Other human lines, including 8/12 bladder cancer and A431 vulval epidermoid cells, but not breast cancer lines, expressed BLCA-38 antigen. Staining occurred in glandular epithelial cells in the majority of frozen, and paraffin-embedded prostate cancer tissues and was occasionally seen in prostatic intraepithelial neoplasia (PIN). No staining was observed in normal cadaver tissues or in benign areas from various other cancer tissues. Conclusions: The BLCA-38 antibody binds to the majority of human prostate cancers but not to normal cells, and has potential for targeting novel therapies in patients with this disease.

Kohler G, Milstein G (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495PubMed

Walker KZ, Russell PJ, Kingsley EA, Philips J, Raghavan D (1989) Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol 142:1578PubMed

Bazinet M, Cote RJ, Cordon-Cardo C, Myc A, Fair WR, Old LJ (1988) Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen. Cancer Res 48:6938PubMed

Leroy M, Teillac P, Rain JD et al (1989) Radioimmunodetection of lymph node invasion in prostatic cancer: the use of iodine-123(¹²³I)-labeled monoclonal-prostatic acid phosphatase 227A F(ab)2 antibody fragments in vivo. Cancer (Phila) 64:1

Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC (1990) Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423PubMed

DeNardo S, Kroger LA, DeNardo G (1999) A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 11:563CrossRefPubMed

Palapattu GS, Reiter RE (2002) Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 168:2615PubMed

Russell PJ, Hewish D, Carter T, Sterling-Levis K, Ow K, Hattarki M, Doughty L, Guthrie R, Shapira D, Molloy PL, Werkmeister JA, Kortt A (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother (in press)

Russell PJ, Wills EJ, Philips J, Jelbart M, Gregory P, Raghavan D (1988) Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: evidence of a common histogenesis? Urol Res 16:79PubMed

10.

Lightfoot DV, Walker KZ, Boniface GR, Hetherington EL, Izard ME, Russell PJ (1991) Dosimetric and therapeutic studies in nude mice xenograft models with 153Samarium-labelled monoclonal antibody, BLCA-38. Antibody Immunoconjugates Radiopharm 4:319

11.

Horoszewicz JS, Leong SS, Chiu TM, Wajsmann ZL, Friedman L, Papsidero L, Kim U, Chai LS, Sandberg AA (1980) The LNCaP cell line, a new model for studies on human prostate carcinoma. Prog Clin Biol Res 37:115PubMed

12.

Mickey D, Stone K, Wunderli H, Mickey G, Vollmer R, Paulson D (1977) Heterotransplantation of human prostatic adenocarcinoma cell line in nude mice. Cancer Res 37:4049PubMed

13.

Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterisation of a human prostate carcinoma cell line (PC-3). Invest Urol 17:16PubMed

14.

Gleave M, Hsieh J-T, Gao C, von Eschenbach AC, Chung LKW (1991) Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753PubMed

15.

Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577PubMed

16.

Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LWK (1994) Derivation of androgen-independent LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57:406PubMed

17.

Pettaway CA, Pathak S, Greene G, Tamirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostate carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627PubMed

18.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493PubMed

19.

Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR et al (1977) Progression of metastatic human prostate cancer to androgen-independence in immunodeficient SCID mice. Nat Med 3:402

20.

Iizumi T, Yazaki T, Kanoh S, Koiso K (1987) Establishment of a new prostatic carcinoma cell line (TSU-PR-1). J Urol 137:1304PubMed

21.

van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 61:6340PubMed

22.

Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D (1990) Clonal analysis of bladder cancer cell line: an experimental model of tumour heterogeneity. Br J Cancer 61:369PubMed

23.

Russell PJ, Jelbart M, Wills EJ, Singh S, Wass J, Raghavan D (1988) Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer 41:74PubMed

24.

Russell PJ, Wass J, Lukeis R, Garson OM, Jelbart M, Wills EJ, Philips J, Brown J, Carrington N, Vincent PC, Raghavan D (1989) Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. Int J Cancer 44:276PubMed

25.

O‘Toole C, Price ZH, Ohnuki Y, Unsgaard B (1978) Ultrastructure, karyology and immunology of a cell line orinated from a transitional cell carcinoma. Br J Cancer 38:64PubMed

26.

Bubenik J, Perlman P, Helmstein K, Moberger G (1970) Cellular and humoral immune responses to human urinary bladder carcinomas. Int J Cancer 5:310PubMed

27.

Zinzar SN, Svet Moldavsky GJ, Fogh J, Mann PE, Arlin Z, Ilescu K, Holland JF (1985) Elaboration of granulocyte-macrophage colony stimulating factor by human tumor cell lines and normal urothelium. Exp Hematol 13:574PubMed

28.

Lundy EG, Sorokin CF, Meltz SK, Glade PR (1977) Reversible inhibition of human peripheral lymphocyte DNA synthesis by an extract of breast cancer cell line SKBR3. J Surg Res 22:654CrossRefPubMed

29.

Koga M, Musgrove EA, Sutherland RL (1990) Differential effects of phorbol ester on epidermal growth factor receptors in estrogen receptor-positive and -negative breast cancer cell lines. Cancer Res 50:4849PubMed

30.

Rizk NN (1982) Scanning electron microscopic study of three human breast cancer cell lines. Acta Cytol 26:714PubMed

31.

Haigler H, Ash JF, Singer SJ, Cohen S (1978) Visualization by fluorescence of the binding and internalization of epidermal gowth factor in human carcinoma cells. Proc Natl Acad Sci U S A 75:3317PubMed

32.

Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom coordinating committee guidelines for the welfare of animals in experimental neoplasia, 2nd edn. Br J Cancer 77:1

33.

Walker KZ, Seymour-Munn K, Keech FK, Axiak SM, Bautovich GH, Morris JC, Basten A (1986) A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells. Eur J Nucl Med 12:461PubMed

34.

Li Y, Tian Z, Rizvi SMA, Bander NH, Allen BJ (2002) In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5:36PubMed

35.

Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexs of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219PubMed

36.

Ow KT, Mameghan H, Lochhead A, Fisher R, Yang J-L, Mameghan J, Andersen S, Russell PJ (1995) The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localised human prostatic adenocarcinoma. Urol Oncol 1:144CrossRef

37.

Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson J (2001) Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248:47CrossRefPubMed

38.

Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004) Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother (in press)

39.

Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629PubMed

40.

Trabulsi EJ, Yao D, Joyce MA, Milowksy M, Kostakoglu L, Vallabhajosula D Nanus D, Goldsmith S, Bander NH (2003) Phase I radioimmunotherapy (RIT) trials of monoclonal antibody (MAB) J591 to the extracellular domain of prostate specific membrane antigen (PSMA_EXT) radiolabeled with yttrium 90 (⁹⁰Y) or lutetium 177 (¹⁷⁷Lu). J Urol 169[Suppl 4]

41.

Trabulsi EJ, Yao D, Kostakoglu L, Vallabhajosula S, Hoyce MA, Milowksy M, Nanus DM, Goldsmith SJ, Bander NH (2003) Targeting metastatic prostate cancer with radiolabeled J591 monoclonal antibody (MAB) specific for the extracellular domain of prostate specific membrane antigen. J Urol 169[Suppl 4]

42.

Ware JL, Paulson DF, Parks SF, Webb KS (1982) Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. Cancer Res 42:1215PubMed

43.

Starling JJ, Wright GL Jr (1985) Disulfide bonding of a human tumor-associated membrane antigen recognized by monoclonal antibody D83.21. Cancer Res 45:804PubMed

44.

Lipford GB, Wright GL Jr (1991) Comparative study of monoclonal antibodies TURP-27 and HNK-1: their relationship to neural cell adhesion molecules and prostate tumor-associated antigens. Cancer Res 51:2296PubMed

45.

Kingsley EA, Russell PJ (1999) Radioimmunotherapy of superficial bladder cancer. In: Riva P (ed) Therapy of malignancies with radioconjugated monoclonal antibodies: present possibilities and future prospectives. Harwood Academic Publishers, The Netherlands, pp 411–441

46.

Li Y, Rivzi SMA, Blair JM (nee Brown), Cozzi PJ, Qu CF, Ow KT, Tam PN, Perkins AC, Russell PJ, Allen BJ (2004) Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with ²¹³Bi-conjugates. Int J Radiation Oncology Biol Phys 59: in press

47.

He XY, Xu Z, Melrose J, Mullowney A, Vasquez M, Queen C, Vexler V, Klingbeil C, Co MS, Berg EL (1998) Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J Immunol 160:1029PubMed

48.

Carter T, Sterling Levis K, Ow K, Doughty L, Hattarki M, Shapira D, Hewish D, Kortt AA, Russell PJ (2004) Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunol Immunother 53:533CrossRefPubMed

Title: Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer
Authors: P. J. Russell
K. T. Ow
P. N. Tam
J. Juarez
E. A. Kingsley
C. F. Qu
Y. Li
P. J. Cozzi
R. Martiniello-Wilks
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0527-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients

Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells

Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

Cancer gene therapy: new horizons in the East

Keynote webinar | Spotlight on antibody–drug conjugates in cancer